Chiome Bioscience Management
Management criteria checks 2/4
Chiome Bioscience's CEO is Shigeru Kobayashi, appointed in Feb 2017, has a tenure of 7.83 years. directly owns 0.39% of the company’s shares, worth ¥63.77M. The average tenure of the management team and the board of directors is 7.7 years and 4.3 years respectively.
Key information
Shigeru Kobayashi
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.8yrs |
| CEO ownership | 0.4% |
| Management average tenure | 7.7yrs |
| Board average tenure | 4.3yrs |
Recent management updates
CEO
Shigeru Kobayashi (71 yo)
7.8yrs
Tenure
Mr. Shigeru Kobayashi, M.E., has been Chief Executive Officer and President at Chiome Bioscience Inc. since February 18, 2017. Mr. Kobayashi has been an Executive Director of Business Planning and Developm...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Executive Director | 7.8yrs | no data | 0.39% ¥ 63.8m | |
| CFO, Head of Corporate Planning Officer & Executive Director | 7.7yrs | no data | 0.070% ¥ 11.3m | |
| Head of Business Development and Executive Officer | 8.9yrs | no data | no data | |
| GM of Development Division & Director | 4.5yrs | no data | 0.037% ¥ 6.0m | |
| Head of Research Division & Executive Director | 1.9yrs | no data | 0.021% ¥ 3.4m |
7.7yrs
Average Tenure
58.5yo
Average Age
Experienced Management: 4583's management team is seasoned and experienced (7.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Executive Director | 8.9yrs | no data | 0.39% ¥ 63.8m | |
| CFO, Head of Corporate Planning Officer & Executive Director | 7.7yrs | no data | 0.070% ¥ 11.3m | |
| GM of Development Division & Director | 1.8yrs | no data | 0.037% ¥ 6.0m | |
| Head of Research Division & Executive Director | 1.8yrs | no data | 0.021% ¥ 3.4m | |
| Audit & Supervisory Board Member | 4.8yrs | no data | no data | |
| Audit & Supervisory Board Member | no data | no data | 0.021% ¥ 3.4m | |
| Independent Outside Director | no data | no data | no data | |
| Audit & Supervisory Board Member | 3.8yrs | no data | no data |
4.3yrs
Average Tenure
63yo
Average Age
Experienced Board: 4583's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 15:36 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chiome Bioscience Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Akitada Iwasa | Daiwa Securities Co. Ltd. |
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |